Key considerations for protein targets: Use ideal body weight (IBW) or adjusted body weight for calculations, not current weight in patients with obesity Distribute protein across meals rather than concentrating in one sitting Monitor for signs of inadequate intake: fatigue, weakness, hair loss, or poor wound healing Reassess needs every 36 months as weight changes Consult with a registered dietitian for personalized recommendations GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists exert their appetite-suppressing effects through multiple mechanisms
The medications work by slowing down the movement of food through the stomach and curbing appetite, thereby causing weight loss
One such development is Tirzepatide, a new class of medication under investigation for type 2 diabetes treatment
In a randomized controlled trial, the GLP-1R agonist exenatide showed reduced alcohol intake in a subgroup of people with both obesity and alcohol use disorder
657-600-9077 Home Location Potential New Patients Physician Services Offered Here Current Patients Acute URI: Common Cold, Cough, and Sore Throat GLP1 Purchase Program Select Page GLP1 Purchase Program
